US Medical Communications

1. Please select one of the following. If you are a health care professional, please make selections from the appropriate lists:
I am a health care professional.
Profession
Specify if other
Specialty
 
I am a patient or consumer.
 
2. Please indicate the product(s) for which you would like information:
 
FLUVIRIN®
RABAVERT®
MSDS Request
Other
 
3. Please give us a little information about yourself:
For Information on our Terms of Use and our Privacy Statement, please click on the links below.
 
Social Title     Professional Title
First Name Initial Last Name
Institution
Department
Address
City State/Province/Territory Zip
Country
Telephone Fax
Email Address
 
4. State your request here. Please be specific.
   
decrease text sizeincrease text size contact help

US Medical Communications

US Medical Communications is the point of contact for inquiries about our marketed vaccine products, pipeline products, and general vaccine-related questions. Business hours are 8:00am - 5:00pm Eastern Time. Call or submit your question online.

1-800-244-7668

Online request form

News

20 June 2008
Dr. Joerg Reinhardt, CEO of Novartis Vaccines and Diagnostics, and Hesse’s Secretary for Economic Affairs, Dr. Alois Rhiel, broke ground together with other representatives of industry and politics today for a €145 million investment project. This symbolic act launched the building operations for the Novartis MARS project.

04 June 2008
Late stage development pipeline with Menveo and MenB vaccines creating meningococcal vaccine franchise with strong growth potential. Novartis leverages research excellence with first in class vaccines in early pipeline, preventing infections from Helicobacter pylori, Group B Streptococcus and other pathogens which pose significant public health challenges.

>>rong portfolio of meningitis vaccines.

>>